Representative Laurel M. Lee (R-Florida) recently bought shares of TuHURA Biosciences NASDAQ: HURA. In a filing disclosed on November 21st, the Representative disclosed that they had bought between $100,001 and $250,000 in TuHURA Biosciences stock on October 18th.
Representative Laurel M. Lee also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of GE Vernova NYSE: GEV on 11/8/2024.
- Purchased $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 10/21/2024.
- Purchased $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 10/7/2024.
- Purchased $50,001 - $100,000 in shares of JPMorgan Chase & Co. NYSE: JPM on 9/10/2024.
TuHURA Biosciences Stock Performance
HURA traded up $0.41 during trading on Friday, hitting $3.76. The stock had a trading volume of 55,195 shares, compared to its average volume of 78,098. TuHURA Biosciences has a one year low of $2.84 and a one year high of $17.36.
Wall Street Analysts Forecast Growth
Separately, Maxim Group started coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a "buy" rating and a $15.00 price target on the stock.
View Our Latest Stock Report on HURA
About Representative Lee
Laurel Lee (Republican Party) is a member of the U.S. House, representing Florida's 15th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2025. Lee (Republican Party) is running for re-election to the U.S. House to represent Florida's 15th Congressional District. She declared candidacy for the Republican primary scheduled on August 20, 2024. Gov. Ron DeSantis (R) appointed Lee to serve as the Florida Secretary of State on January 28, 2019, after the resignation of Michael Ertel on January 24. Lee resigned on May 16, 2022. Lee was a judge of the 13th Judicial Circuit Court in Florida from 2013 to 2019. She was appointed to the court by Gov. Rick Scott (R) in May 2013. She was elected to the position in 2014. Laurel Lee earned undergraduate and law degrees from the University of Florida. Lee's career experience includes working as an attorney with Carlton Fields, P.A., an assistant federal public defender and assistant U.S. attorney with the United States District Court for the Middle District of Florida, and a law clerk to James S. Moody on the United States District Court for the Middle District of Florida.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
